The transaction is expected to be immediately accretive to Thermo Fisher’s adjusted EPS after close. Thermo Fisher expects to realize total synergies of $200 million by year three following the close, consisting of $150 million of cost synergies and $50 million of adjusted operating income benefit from revenue synergies. Explore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances. News, testing solutions and stories covering global efforts in the fight against COVID-19. Qiagen shares surged 19% to 37.84 euros after Thermo Fisher Scientific said it would buy the diagnostics firm for 39 euros per share in cash, which is a 23% premium to Monday’s close. Get this delivered to your inbox, and more info about our products and services.

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business.

Qiagen

QIAGEN is a leading provider of life science and molecular diagnostic solutions and employs approximately 5,100 people at 35 locations in more than 25 countries. Its sample preparation technologies are used to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples. The company’s assay technologies are then used to amplify and enrich these biomolecules to make them readily accessible for analysis. In addition, QIAGEN’s instruments can be used to automate these workflows, while its bioinformatics systems provide customers with relevant, actionable insights.

And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. QGEN’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. LLC are serving as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel. For QIAGEN, Goldman Sachs International is serving as lead financial advisor and Barclays Bank PLC is serving as financial advisor, while De Brauw Blackstone Westbroek NV, Linklaters LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C. Delivers Attractive Financial Benefits through the PPI Business System, Including Proven Integration Approach.

Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing

It can also be calculated by dividing the company’s Market Cap by the Net Profit. Japan to become the latest of more than 100 countries where QIAstat-Dx is available for molecular testing in diagnosing over 20 respiratory diseases from one patient sample // Generates actionable res… The acquisition offer was terminated on August 13, 2020, having only reached the threshold of 47% of shareholder approval, below the minimum 66.6% required as per the agreement. Davidson Kempner was notable as having continued to reject the bid. Because of the lapsed offer, QIAGEN was required to reimburse $95 Million to Thermo Fisher in expenses.[37] Within a week of the collapse of the merger, QIAGEN’s stock rose over 10%. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams.

Qiagen’s roots are in products that help scientists prepare biological samples for various experiments, and sample preparation products still accounted for 38% of sales in 2021, although inflated as a percentage of sales due to the COVID-19 health crisis. Qiagen https://forex-world.net/software-development/history-of-personal-computers/ remains a key leader in this niche, and we expect Qiagen to continue to invest to maintain or improve in that business in the long run. Qiagen NV raised its outlook for 2020 and 2021 on Tuesday after increasing production amid the coronavirus pandemic.

Financial Performance

The Germany-based provider of sample and assay technologies now expects net sales to grow by at least 32%… We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements https://trading-market.org/brokerage-company-definition-2020/ or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

Slumped 4.5% in morning trading Monday, reversing an earlier intraday gain of as much 1.7%, after the Netherlands-based biotechnology company provided an upbeat second-quarter revenue outlook, citing… Our desire to innovate is driven by our customers passion in their fields. From doctors seeking solutions to diagnose and prevent disease, to researchers conquering new scientific frontiers and translating genomic insights into new medicines, we are inspired by their discoveries and breakthroughs. In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets.

Kepler Capital Keeps Their Hold Rating on Qiagen (QGEN)

Read our equity story, financial disclosures and how we create shareholder value. Learn about who we are and what we do to make improvements in life possible. Up to date protocols and list of COVID-19 testing and research solutions. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. 52 week high is the highest price of a stock in the past 52 weeks, or one year.

• LLC are serving as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel.
• A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
• The acquisition offer was terminated on August 13, 2020, having only reached the threshold of 47% of shareholder approval, below the minimum 66.6% required as per the agreement.
• As an example, with an expanded portfolio, Thermo Fisher will be able to provide research customers with broader capabilities to accelerate discovery and enable scientific breakthroughs.
• Qiagen NV lost about one-fifth of its market value on Thursday after the Dutch biotechnology company said earlier this week that it would focus on its stand-alone business strategy, rejecting possible suitors.

Thermo Fisher will be able to leverage its extensive commercial reach, including its Fisher Scientific customer channels and comprehensive e-commerce platforms, to expand customer access to QIAGEN’s product portfolio. Furthermore, https://currency-trading.org/strategies/a-complete-guide-to-futures-scalping-strategy/ given Thermo Fisher’s leading presence in high-growth and emerging markets, QIAGEN will be able to further penetrate these regions. Market cap, also known as market capitalization, is the total market value of a company.